Miranda Schmalfuhs
Miranda Schmalfuhs is the associate group social media editor of Pharmaceutical Executive, Pharmaceutical Commerce, and Applied Clinical Trials and can be reached at mschmalfuhs@mjhlifesciences.com.
Articles
How Can We Foster Collaboration Across the Healthcare Ecosystem to Optimize DTP?
December 13th 2024In this part of her Pharmaceutical Executive video interview, Angela Tenuta, President, Full Service Agencies, at EVERSANA INTOUCH, elaborates on the challenges and strategies for fostering collaboration between different industry groups and pharma companies for the Direct-to-Patient model.
Quantifying the Benefits of AI-Powered Patient Adherence Programs
December 9th 2024In this part of his Pharmaceutical Executive video interview, Bill Grambley, CEO of AllazoHealth, identifies which metrics and KPIs can be used to measure the effectiveness of AI-powered patient engagement and adherence programs.
How Can Pharma Navigate the Regulatory Maze of AI-Powered Interventions?
December 6th 2024In this part of his Pharmaceutical Executive video interview, Bill Grambley, CEO of AllazoHealth, discusses how pharmaceutical companies navigate the evolving regulatory landscape to ensure that AI-powered interventions comply with relevant regulations and guidelines.
Personalized AI-Powered Solutions for Better Patient Adherence
December 4th 2024In this part of his Pharmaceutical Executive video interview, Bill Grambley, CEO of AllazoHealth, identifies how AI can identify patients at risk of medication non-adherence and intervene early to prevent negative outcomes.
Using AI to Predict and Influence Patient Behavior
December 3rd 2024In this part of his Pharmaceutical Executive video interview, Bill Grambley, CEO of AllazoHealth, explains how AI can be leveraged to create highly personalized patient engagement strategies, tailored to individual needs and preferences.
